HLB’s anticancer drug candidate shows world’s longest survival duration against liver cancer
Sept 8, 2022
HLB’s precision cancer drug Rivoceranib has demonstrated the world’s longest median overall survival, or mOS, in phase 3 clinical trials of liver cancer, the South Korean biopharmaceutical company said Thursday. According to HLB, Rivoceranib’s mOS recorded 22.1 months to mark the first drug in the world to break the 20-month barrier against liver cancer. The company earlier released the abstract of phase 3 concomitant clinical trials of Rivoceranib and anticancer drug Camreli